Advertisement
Advertisement
KLRS
Kalaris Therapeutics, Inc. Common Stock
2.42
USDSponsored
+0.06
+2.54%
Nov 06, 15:59 UTC -5
Closed
After-Market
2.43
+0.01
+0.41%
Kalaris Therapeutics, Inc. Common Stock (KLRS) Earnings
KLRS Earnings Reports
Positive Surprise Ratio
KLRS beat 13 of 22 last estimates.
59%
Next Report
Tomorrow
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.51
Implied change from Q2 26 (Revenue/ EPS)
--
/+6.25%
Implied change from Q3 25 (Revenue/ EPS)
--
/-20.31%
Kalaris Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 11, 2026, KLRS reported earnings of -0.48 USD per share (EPS) for Q2 26, beating the estimate of -0.50 USD, resulting in a 4.93% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.76% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.51 USD, with revenue projected to reach -- USD, implying an increase of 6.25% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunocore Holdings plc - ADR
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.28
Surprise
-104.08%
Entera Bio Ltd. Ordinary Shares
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.06
Actual
-$0.11
Surprise
-58.50%
Vogenx Inc Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.47
Surprise
-187.99%
Agenus Inc.
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.27
Actual
$0.02
Surprise
+107.26%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
-$0.02
Surprise
-132.68%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Bio-Techne Corp.
Report Date
Nov 06, 2026 For Q1 27
Estimate
$0.44
Actual
$0.44
Surprise
-1.96%
Aligos Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$2.21
Actual
-$2.09
Surprise
+5.58%
CervoMed Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.49
Actual
-$0.39
Surprise
+21.97%
Creative Medical Technology Holdings, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.40
Surprise
-63.40%
FAQ
What were Kalaris Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Kalaris Therapeutics, Inc. Common Stock reported EPS of -$0.48, beating estimates by 4.93%, and revenue of $0.00, 0% as expectations.
How did the market react to Kalaris Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 0.76%, changed from $3.94 before the earnings release to $3.97 the day after.
When is Kalaris Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Kalaris Therapeutics, Inc. Common Stock's next earnings report?
Based on 6
analysts, Kalaris Therapeutics, Inc. Common Stock is expected to report EPS of -$0.51 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.